<DOC>
	<DOCNO>NCT00967707</DOCNO>
	<brief_summary>The primary objective study develop pharmacokinetic ( PK ) pharmacokinetic-pharmacodynamic ( PK-PD ) model gabapentin patient neuropathic pain . The secondary objective investigate whether adjuvant therapy venlafaxine donepezil contribute 1 ) improve analgesic efficacy 2 ) improve health-related quality life ( assessed SF-36 questionnaire ) neuropathic pain patient treat gabapentin .</brief_summary>
	<brief_title>Population Pharmacokinetic-pharmacodynamic ( PK-PD ) Modeling Co-administered Gabapentin Neuropathic Pain</brief_title>
	<detailed_description>Neuropathic pain estimate affect 2-3 % population condition difficult treat conventional analgesic . The drug first choice typically tricyclic antidepressant drug ( TCA ) antiepileptic drug gabapentin . TCAs well-documented effect , use commonly interrupt due intolerable adverse effect . Gabapentin , hand , generally well tolerated patient . Clinical trial proven gabapentin efficacious neuropathic pain various origin . Nevertheless , monotherapy seldom sufficient management severe neuropathic pain . Combination therapy , e.g . gabapentin analgesic complementary mechanism action , may rational strategy obtain improved result low dose few side effect . Although many neuropathic pain patient receive combination drug , absence clinical evidence optimal drug combination . Gabapentin bind alpha-2-delta subunit presynaptic voltage-gated calcium channel , result modulation release neurotransmitter presynaptic nerve terminal . Recent study animal model neuropathic pain show gabapentin effective supraspinal structure , activate descend pain inhibitory noradrenergic-cholinergic cascade . Thus , might possible potentiate analgesic effect gabapentin concomitant administration drug able prolong action noradrenaline acetylcholine synapse cleft . In study , adjuvant effect noradrenaline serotonin reuptake inhibitor venlafaxine cholinesterase inhibitor donepezil investigate neuropathic pain patient treat gabapentin . The study consist two period . All patient treat gabapentin first period , receive randomise adjuvant therapy venlafaxine donepezil second period . Repeated pain intensity rating blood sample analysis gabapentin plasma concentration collect one dose interval gabapentin end period . Data analyse mean nonlinear mixed effect modeling . The NONMEM programme use develop model describe PK PK-PD relationship gabapentin patient neuropathic pain . The potential effect concomitant treatment venlafaxine donepezil evaluate covariate analysis develop PK PK-PD model gabapentin .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Diagnosis posttraumatic neuropathic pain Spontaneous pain intensity ≥ 40 VAS ≥ 4 NRS Man woman ≥ 18 year old Informed consent study participation Presence type pain strong strong neuropathic pain Impaired kidney function ( GFR &lt; 30 ml/min ) Uncontrolled cardiovascular disease/hypertonia Uncontrolled narrowangle glaucoma Uncontrolled pulmonary disease Epilepsia Pregnancy Nursing Woman childbearing potential use contraception planning become pregnant study period Disability understand cooperate study procedure Allergy study medication Concomitant participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>